Clinical trial pipeline · Data from ClinicalTrials.gov
See which Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) trials you may qualify forThe main objective of this study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of a…
This study is an open-label, exploratory, prospective clinical trial with dose escalation(according to "3+3" design), to evaluate the safety and tolerability of…
The MESO7 study is a prospective observational research project designed to investigate the mechanisms of resilience and neurodegeneration in neurological disea…
The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectru…
MOG-IgG associated disease (MOGAD) is a rare inflammatory disease of the central nervous system recently described. Initially reported as monophasic, data from…
CLUE is a prospective study to determine structural and functional changes of brain and spinal cord, as well as the inflammatory environment in patients with ne…
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte…
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) is an inflammatory demyelinating disorder of the central nervous system characterized by…
The purpose of the study is to evaluate the safety and efficacy of Tocilizumab in MOGAD.